Recently it was announced that Fluor Corporation of Irving, TX landed a $1.2 billion contract to design and build the $2 billion manufacturing facility for Novo Nordisk‘s diabetes API (Active Pharmaceutical Ingredient) in North Carolina. News reports reveal the world-class facility designed to provide diabetes patients with modern treatments is the largest investment in a life sciences facility in the …
Pharma Coding – Novo Nordisk Pledges To Put A Lid On Price Increases
Recently it was announced by Novo Nordisk U.S.‘ EVP, Jakob Riis, that the Denmark-based company pledges to limit increases in drug prices in the U.S., acknowledging the difficulty many patients with diabetes have when it comes to the ability to afford their medications. Riis said in an article posted on the Novo Nordisk A/S website that future increases in price …
Fidia Pharmaceutical Introduces New Packaging For Hyalo Gyn®
Recently it was announced that a global leader in hyaluronic acid products, Fidia Farmaceutical S.p.a. and its wholly owned subsidiary Fidia Pharma USA Inc., introduced new product packaging for its HYALO GYN® vaginal hydrating gel, while the formulation of the product would remain the same. The company specializes in R & D and manufacturing of products based on HA, or …
U.S. Still Largest Market For Medical Devices And Pharmaceuticals
According to The Association for Packaging and Processing Technologies (PMMI), the U.S. remains the largest market for medical devices and pharmaceuticals, even as the demand on a global scale continues to increase. In its report Pharmaceutical and Medical Devices: Trends and Opportunities in Packaging Operations, released by PMMI at PACK and Pharma Expo 2016, the association found that some of …
Pharma News – Novartis Acquires Selexys Pharmaceuticals
Recently in pharma news it was announced that Basel, Switzerland-based Novartis, a global healthcare company, has acquired Oklahoma City-based Selexys Pharmaceuticals, a company specializing in inflammatory and hematological disorders, for $665 million. According to news reports, Selexys was purchased following a Phase II trial focusing on the use of the anti-P-selectin antibody SelG1 for reducing the instance of vaso-occlusive crises …